These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27461631)

  • 81. Association between methylenetetrahydrofolate reductase tagging polymorphisms and susceptibility of hepatocellular carcinoma: a case-control study.
    Zhang S; Lin J; Jiang J; Chen Y; Tang W; Liu L
    Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31694048
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Identification of miR-423 and miR-499 polymorphisms on affecting the risk of hepatocellular carcinoma in a large-scale population.
    Ma Y; Wang R; Zhang J; Li W; Gao C; Liu J; Wang J
    Genet Test Mol Biomarkers; 2014 Jul; 18(7):516-24. PubMed ID: 24854593
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma.
    Son MS; Jang MJ; Jeon YJ; Kim WH; Kwon CI; Ko KH; Park PW; Hong SP; Rim KS; Kwon SW; Hwang SG; Kim NK
    Gene; 2013 Jul; 524(2):156-60. PubMed ID: 23632240
    [TBL] [Abstract][Full Text] [Related]  

  • 84. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
    Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
    Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Rs3746444 T>C locus in miR-499 increases the susceptibility to hepatocellular carcinoma: A meta-analysis 14812 subjects.
    Jiang JK; Chen HS; Tang WF; Chen Y; Lin J
    World J Gastrointest Oncol; 2023 Jan; 15(1):171-185. PubMed ID: 36684045
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma.
    Jiang YJ; Zhong JH; Zhou ZH; Qiu MQ; Zhou XG; Liu YC; Huo RR; Liang XM; Chen Z; Lin QL; Yu XY; Yu HP
    Cancer Med; 2019 May; 8(5):2545-2552. PubMed ID: 30883040
    [TBL] [Abstract][Full Text] [Related]  

  • 87. DNA repair gene XRCC3 polymorphisms and bladder cancer risk: a meta-analysis.
    Peng Q; Mo C; Tang W; Chen Z; Li R; Zhai L; Yang S; Wu J; Sui J; Li S; Qin X
    Tumour Biol; 2014 Mar; 35(3):1933-44. PubMed ID: 24104500
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Single Nucleotide Polymorphisms in
    Bei C; Liu S; Yu X; Qiu M; Tang B; Liao W; He S; Yu H
    Biomed Res Int; 2018; 2018():1540201. PubMed ID: 30662901
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Association between the XRCC3 C241T polymorphism and lung cancer risk in the Asian population.
    Tian X; Tian Y; Ma P; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Jiang Y
    Tumour Biol; 2013 Oct; 34(5):2589-97. PubMed ID: 23749486
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Interferon-γ +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis.
    Zhou H; Wang L; Li X; Song J; Jiang T; Wu X; Zhou S
    Med Sci Monit; 2015 Mar; 21():689-93. PubMed ID: 25739411
    [TBL] [Abstract][Full Text] [Related]  

  • 91. GSTT1 null genotype contributes to hepatocellular carcinoma risk: a meta-analysis.
    Chen KJ; Fan F; Wang Y; Wei GT; Hu L; Xu F
    Tumour Biol; 2014 Jan; 35(1):213-8. PubMed ID: 23959468
    [TBL] [Abstract][Full Text] [Related]  

  • 92. X-ray repair cross-complementing group 1 polymorphisms and hepatocellular carcinoma: a meta-analysis.
    Xie T; Wang ZG; Zhang JL; Liu H
    World J Gastroenterol; 2012 Aug; 18(31):4207-14. PubMed ID: 22919255
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Five common functional polymorphisms in microRNAs (rs2910164, rs2292832, rs11614913, rs3746444, rs895819) and the susceptibility to breast cancer: evidence from 8361 cancer cases and 8504 controls.
    Dai ZJ; Shao YP; Wang XJ; Xu D; Kang HF; Ren HT; Min WL; Lin S; Wang M; Song ZJ
    Curr Pharm Des; 2015; 21(11):1455-63. PubMed ID: 25483824
    [TBL] [Abstract][Full Text] [Related]  

  • 94. MicroRNA-499 Rs3746444 polymorphism and biliary atresia.
    Shan Y; Shen N; Han L; Chen Q; Zhang J; Long X; Xia Q
    Dig Liver Dis; 2016 Apr; 48(4):423-8. PubMed ID: 26795543
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.
    Jiang G; Yu K; Shao L; Yu X; Hu C; Qian P; Xie H; Li J; Zheng J; Zheng S
    BMC Cancer; 2015 Apr; 15():314. PubMed ID: 25927412
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: evidence from published literatures.
    Xu Y; Gu L; Pan Y; Li R; Gao T; Song G; Nie Z; Chen L; Wang S; He B
    PLoS One; 2013; 8(6):e65123. PubMed ID: 23750236
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population.
    Bi J; Zhong C; Li K; Chu H; Wang B
    Biomed Res Int; 2013; 2013():138785. PubMed ID: 23984316
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea.
    Shin SP; Kim NK; Kim JH; Lee JH; Kim JO; Cho SH; Park H; Kim MN; Rim KS; Hwang SG
    World J Gastroenterol; 2015 Dec; 21(46):13064-72. PubMed ID: 26672513
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Correlation between
    Huang Z; Guo X; Zhang G; Liang L; Nong B
    Int J Biol Markers; 2019 Jun; 34(2):117-122. PubMed ID: 30852978
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Associations between single nucleotide polymorphisms in RYBP and the prognosis of hepatocellular carcinoma in a Chinese population.
    Zhu X; Wang Z; Qiu X; Tan C; Yu H; Bei C; Qin L; Ren Y; Tan S
    Carcinogenesis; 2017 May; 38(5):532-540. PubMed ID: 28369212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.